Thyroid Porcine
| Evidence Level: L5 | Predicted Indications: 6 |
Table of Contents
Thyroid Porcine: Migraine disorder
One-Sentence Summary
Porcine thyroid is a natural thyroid hormone preparation (containing T3/T4) that is marketed in Canada under three licences. The TxGNN model predicts it may be effective for migraine disorder, but there are currently 0 clinical trials and 0 publications supporting this direction, so the prediction rests on model output alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Migraine disorder |
| TxGNN Prediction Score | 0.9991 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 3 of 3) |
| Number of DINs | 3 (marketed: 3) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, porcine thyroid is a source of exogenous thyroid hormones (T3/T4) and is used to replace deficient thyroid hormone. Its mechanistic link to migraine is therefore indirect.
The only plausible connection is epidemiological: hypothyroidism has been reported as a comorbidity or risk factor for migraine and other headache disorders. Correcting thyroid deficiency might help in that subgroup, but no trial or publication in the data compiled for this report supports this. The high score (0.9991) comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence.
Other top predictions show the same pattern:
- Migraine with brainstem aura and migraine with or without aura, susceptibility to: these inherit the general migraine prediction. The second is a genetic susceptibility entry rather than a treatable condition.
- Raynaud disease (0.9945): hypothyroidism can cause cold intolerance and vasospasm, but the link is indirect.
- Atrophoderma vermiculata and ulerythema ophryogenesis: rare follicular skin disorders with no plausible thyroid hormone mechanism. These appear to be TxGNN model (deep learning) artifacts.
- Prinzmetal angina (0.9910): thyroid hormone raises heart rate, oxygen demand and adrenergic sensitivity, so it could worsen coronary vasospasm. This is a safety concern.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 00023949 | THYROID | Not stated | Not stated |
| 00023957 | THYROID | Not stated | Not stated |
| 00023965 | THYROID | Not stated | Not stated |
Safety Considerations
- Drug Interactions: The interaction screening found 99 interacting drugs. The 20 listed in the data are all rated Moderate. They include:
- Antidiabetic agents: acarbose, metformin, pioglitazone, alogliptin, albiglutide, dulaglutide, canagliflozin, dapagliflozin, empagliflozin, chlorpropamide and acetohexamide
- Acid-suppressing drugs: omeprazole, rabeprazole and dexlansoprazole
- Minerals and antacids: calcium phosphate, calcium acetate and magnesium oxide
- Sympathomimetic agents: epinephrine, isometheptene and diethylpropion
- Disease-specific cautions (from the mechanistic review above):
- Coronary vasospasm and ischaemic disease: thyroid hormone may worsen these and needs careful dosing.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: All ten predictions are supported by model output only, with no clinical trials or publications (Evidence Level L5). The migraine link is indirect, and several other predictions are implausible or carry safety concerns (hyperthyroidism, Prinzmetal angina).
To proceed, the following is needed:
- Health Canada package insert warnings and contraindications (a blocking gap for safety screening)
- Approved indication, dosage form and manufacturer details for the three licences
- Mechanism of action data
- A literature and trial search on thyroid status and migraine, to test whether any benefit is limited to patients with hypothyroidism
- A cardiovascular and drug-interaction risk assessment before any new-indication study
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.